Bio-View Valuation
Is BIOV undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BIOV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate BIOV's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BIOV's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BIOV?
Key metric: As BIOV is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is BIOV's PE Ratio? | |
|---|---|
| PE Ratio | 36.5x |
| Earnings | ₪887.00k |
| Market Cap | ₪32.39m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.5x |
| Enterprise Value/EBITDA | 40.7x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does BIOV's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 42.4x | ||
EPIT Epitomee Medical | 28.4x | n/a | ₪280.8m |
BWAY BrainsWay | 122.9x | 63.6% | ₪683.0m |
NISA Nissan Medical Industries | 7.7x | n/a | ₪150.2m |
MEDIC Medicon Hellas | 10.6x | n/a | €8.9m |
BIOV Bio-View | 36.5x | n/a | ₪32.4m |
Price-To-Earnings vs Peers: BIOV is good value based on its Price-To-Earnings Ratio (36.5x) compared to the peer average (42.4x).
Price to Earnings Ratio vs Industry
How does BIOV's PE Ratio compare vs other companies in the Asian Medical Equipment Industry?
| 3 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: BIOV is expensive based on its Price-To-Earnings Ratio (36.5x) compared to the Asian Medical Equipment industry average (25.7x).
Price to Earnings Ratio vs Fair Ratio
What is BIOV's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 36.5x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BIOV's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.